Immunotherapy with NK cell, rituximab and rhu-GMCSF in non-myeloablative allogeneic stem cell transplantation.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Granulocyte colony-stimulating factors (Primary) ; Rituximab (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2017 Planned End Date changed from 1 Sep 2012 to 1 Sep 2018.
- 08 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 03 Mar 2016 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.